FORM
6-K
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
dated
September 27, 2023
Commission
File Number 0-51504
GENETIC
TECHNOLOGIES LIMITED
(Exact
Name as Specified in its Charter)
N/A
(Translation
of Registrant’s Name)
60-66
Hanover Street
Fitzroy
Victoria
3065 Australia
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
☐ No ☒
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
September 27, 2023
|
GENETIC TECHNOLOGIES LIMITED |
|
|
|
By: |
/s/
Tony Di Pietro |
|
Name: |
Tony Di Pietro |
|
Title: |
Company Secretary |
EXHIBIT
INDEX
Exhibit
99.1
ASX
Market Announcement | ![](https://www.sec.gov/Archives/edgar/data/1166272/000149315223033835/ex99-1_001.jpg) |
Genetype
and Gold Coast Private Hospital Announce Precision Medicine Pilot
Melbourne,
Australia, 27 September 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”)
– a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce a partnership with the
Gold Coast Private Hospital (GCPH), a member of Healthscope, to establish a Precision Medicine Clinic at the hospital.
Highlights:
● | Partnership
will be initiated with a 50-patient pilot study to establish workflow and patient reporting. |
● | Pilot
study will utilise geneType Multi-risk test combined with Pharmacogenomics (PGx) tests, providing
a comprehensive wellness profile for GCPH patients. |
● | Patient
recruitment
to commence immediately. |
● | Positive
outcomes could enable the rollout of additional Precision Medicine Clinics throughout the
Healthscope network. |
● | Gold
Coast Private Hospital by Healthscope is a 336 bed, 22 theatre hospital and home to leading
doctors and surgeons from around the world. |
● | Healthscope
is Australia’s only national private hospital operation and healthcare provider with
a network of 42 hospitals that service every state and territory with 19,000 employees. |
According
to the US Food and Drug Administration (FDA), Precision Medicine, also known as “personalised medicine” is an innovative
approach to tailoring disease prevention and treatment that takes into account differences in people’s genes, environments, and
lifestyles. The goal of precision medicine is to target the right treatments to the right patients at the right time. Utilising GTG’s
geneType Multi-test and PGx tests will be an important step in improving health outcomes for GCPH’s patients.
Research
Manager for the Gold Coast private hospital, Michelle Ferrari Cestari, commented. “We have a clear vision for a Precision Medicine
Clinic that focuses on preventative care, wellness and creating proactive patient pathways that lead to early detection, and better treatment
of the common diseases”
According
to GTG’s CEO, Simon Morriss “We are seeing a seismic shift in healthcare today, with acknowledgement of the important contribution
that risk assessments tests such as geneType and PGx can make to Precision Medicine. Being able to identify those people at higher risk
of certain diseases and those who are more likely to respond to appropriate treatments is major step forward in improving patient health
outcomes. We are very excited to be supporting Healthscope with this initiative.”
-END-
Enquiries
Investor
Relations
Adrian
Mulcahy
Automic
Markets
M:
+61 438 630 411
E:
adrian.mulcahy@automicgroup.com.au
Genetic Technologies Limited
www.genetype.com
info@gtglabs.com
ABN 17 009 212 328
|
60-66 Hanover Street
Fitzroy Victoria 3065
Australia
+61 3 8412 7000
|
Authorized
for release by the board of directors of Genetic Technologies Limited.
About
Genetic Technologies Limited
Genetic
Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests
in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment
tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform
that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and
individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues
to develop risk assessment products. For more information, please visit www.genetype.com
About
Gold Coast Private Hospital by Healthscope
Gold
Coast Private Hospital by Healthscope is a 336 bed and 22 theatre hospital is home to leading doctors and surgeons. The focus is on the
patient with and expert team of surgeons, specialist doctors, dedicated nurses and other supporting health professionals ensuring holistic
health care experience is the best it can be.
Offering
the latest technology, and truly impressive state-of-the-art facilities, they attract leading doctors and surgeons from across the world.
This, in turn, has meant that we are the Gold Coast hospital of choice for GPs, consultants and, of course, patients who quite rightly
place a premium on their health and wellbeing https://goldcoastprivatehospital.com.au
Healthscope
is Australia’s only national private hospital operation and healthcare provider with a network of 42 hospitals that service every
state and territory. With over 19,000 people and provide work for nearly as many accredited medical practitioners. Our people are known
for achieving exceptional clinical outcomes, transparent public reporting and positive patient feedback that leads the industry. No matter
the role, every day the people make a difference to the lives of patients, their families and carers, and it is a privilege to be part
of their care. https://healthscope.com.au/
Forward
Looking Statements
This
announcement may contain forward-looking statements about the Company’s expectations, beliefs or intentions regarding, among other
things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made
or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as “believe,” “expect,” “intend,” “plan,” “may,” “should”
or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not
limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made
by or with the approval of one of the Company’s authorized executive officers. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual
results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause
the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings with the
ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities
values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any
obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by law.
Genetic Technologies Limited
www.genetype.com
info@gtglabs.com
ABN 17 009 212 328 |
60-66 Hanover Street
Fitzroy Victoria 3065
Australia
+61 3 8412 7000 |
Genetic Technologies (PK) (USOTC:GNTLF)
Historical Stock Chart
From May 2024 to Jun 2024
Genetic Technologies (PK) (USOTC:GNTLF)
Historical Stock Chart
From Jun 2023 to Jun 2024